EGFR mutation	Solid Tumor	EGFR mutation	Solid Tumor	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2	ORIC-114 Sensitive: C2 – Inclusion Criteria ORIC-114 Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	ORIC-114 Sensitive: C3 – Early Trials ORIC-114 Sensitive : C3	ORIC-114 Sensitive: C3 – Early Trials ORIC-114 Sensitive : C3
EGFR H773_V774insH	Non Small Cell Lung Cancer	EGFR H773_V774insH	Non Small Cell Lung Cancer	ORIC-114 Sensitive: D – Preclinical ORIC-114 Sensitive : D	ORIC-114 Sensitive: D – Preclinical ORIC-114 Sensitive : D

enozertinib (ORIC-114)

Associations
(4)